{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:57:40Z","timestamp":1787673460510,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.phrs.2021.105954","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T13:04:01Z","timestamp":1635167041000},"page":"105954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites"],"prefix":"10.1016","volume":"178","author":[{"given":"Alejandra","family":"Mart\u00ednez-Ch\u00e1vez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy H.C.","family":"Loos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Lebre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs M.","family":"Tibben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred H.","family":"Schinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105954_bib1","doi-asserted-by":"crossref","unstructured":"N. Harbeck, F. Penault-Llorca, J. Cortes, M. Gnant, N. Houssami, P. Poortmans, K. Ruddy, J. Tsang, F. Cardoso, Breast Cancer, 2019. \u3008https:\/\/doi.org\/10.1038\/s41572\u2013019-0111\u20132\u3009.","DOI":"10.1038\/s41572-019-0111-2"},{"key":"10.1016\/j.phrs.2021.105954_bib2","first-page":"1","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"0","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2021.105954_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O\u2019Leary","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.105954_bib4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","article-title":"Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine","volume":"32","author":"Gelbert","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.phrs.2021.105954_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of Abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non\u2013small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2021.105954_bib6","unstructured":"FDA Center for drug evaluation and Rsearch, Multi-discipline Review of Abemaciclib, 2017."},{"key":"10.1016\/j.phrs.2021.105954_bib7","unstructured":"Committee for Medicinal Products for Human Use (CHMP), Public assessment report abemaciclib, (2018). \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/verzenios-epar-public-assessment-report_en.pdf\u3009."},{"key":"10.1016\/j.phrs.2021.105954_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104686","article-title":"A unique CDK4\/6 inhibitor: current and future therapeutic strategies of abemaciclib","volume":"156","author":"Chong","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105954_bib9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/cpt.1710","article-title":"Protein expression and functional relevance of efflux and uptake drug transporters at the blood\u2013brain barrier of human brain and glioblastoma","volume":"107","author":"Bao","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2021.105954_bib10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/cpt.77","article-title":"Blood-brain barrier: an impediment to neuropharmaceuticals","volume":"97","author":"Henderson","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2021.105954_bib11","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.phrs.2021.105954_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.addr.2012.09.027","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"64","author":"Schinkel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105954_bib13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","article-title":"The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox)","volume":"13","author":"Szak\u00e1cs","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2021.105954_bib14","article-title":"Membrane transporters in drug development","author":"Giacomini","year":"2010","journal-title":"Int. Transpporter Consort., Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105954_bib15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1081\/DMR-120026871","article-title":"Clinical relevance of P-glycoprotein in drug therapy","volume":"35","author":"Lin","year":"2003","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.phrs.2021.105954_bib16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bcp.2012.01.002","article-title":"Role of breast cancer resistance protein (BCRP\/ABCG2) in cancer drug resistance","volume":"83","author":"Natarajan","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105954_bib17","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1124\/dmd.114.062745","article-title":"Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft","volume":"43","author":"Raub","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2021.105954_bib18","doi-asserted-by":"crossref","first-page":"32167","DOI":"10.1074\/jbc.273.48.32167","article-title":"Functional multidrug resistance protein (MRP1) lacking the N- terminal transmembrane domain","volume":"273","author":"Bakos","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105954_bib19","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI928","article-title":"Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA","volume":"101","author":"Evers","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2021.105954_bib20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1021\/mp1003898","article-title":"Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier","volume":"8","author":"Poller","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2021.105954_bib21","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/jnci\/92.20.1651","article-title":"Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan","volume":"92","author":"Jonker","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.phrs.2021.105954_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114225","article-title":"Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC\u2013MS \/ MS","volume":"203","author":"Mart\u00ednez-Ch\u00e1vez","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.phrs.2021.105954_bib23","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1073\/pnas.94.8.4028","article-title":"Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins","volume":"94","author":"Schinkel","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2021.105954_bib24","doi-asserted-by":"crossref","first-page":"8996","DOI":"10.1158\/0008-5472.CAN-09-2915","article-title":"Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity","volume":"69","author":"Van Waterschoot","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105954_bib25","doi-asserted-by":"crossref","DOI":"10.1007\/s00216-019-01932-w","article-title":"Development and validation of a bioanalytical method for the quantification of the CDK4\/6 inhibitors abemaciclib, palbociclib and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry","volume":"411","author":"Mart\u00ednez-Ch\u00e1vez","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.phrs.2021.105954_bib26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.phrs.2021.105954_bib27","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1007\/s11095-014-1599-5","article-title":"Genomic knockout of endogenous canine P-glycoprotein in wild-type, human P-glycoprotein and human BCRP transfected MDCKII cell lines by zinc finger nucleases","volume":"32","author":"Gartzke","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.105954_bib28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jcph.1584","article-title":"Predicting clinical effects of CYP3A4 modulators on abemaciclib and active metabolites exposure using physiologically based pharmacokinetic modeling","volume":"60","author":"Posada","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105954_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2016.10.015","article-title":"Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo","volume":"124","author":"Wu","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105954_bib30","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2021.105954_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0305-7372(03)00105-1","article-title":"The management of brain metastases","volume":"29","author":"Patchell","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2021.105954_bib32","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc3053","article-title":"Brain metastases as preventive and therapeutic targets","volume":"11","author":"Steeg","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2021.105954_bib33","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor \u2013 positive breast cancer","volume":"26","author":"Tolaney","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105954_bib34","article-title":"ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost ll ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain","volume":"2","author":"de Gooijer","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.phrs.2021.105954_bib35","first-page":"47","article-title":"The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment","volume":"9","author":"Mittal","year":"2016","journal-title":"Pharmgenomics. Pers. Med."},{"key":"10.1016\/j.phrs.2021.105954_bib36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00003088-200544040-00002","article-title":"Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance","volume":"44","author":"Rochat","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2021.105954_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/pgs.12.187","article-title":"CYP3A4\u260522: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy","volume":"14","author":"Elens","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2021.105954_bib38","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/jps.23600","article-title":"Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system","volume":"102","author":"Miyajima","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.phrs.2021.105954_bib39","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s10637-015-0266-y","article-title":"P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4\/6 inhibitor palbociclib","volume":"33","author":"de Gooijer","year":"2015","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.phrs.2021.105954_bib40","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1021\/acs.molpharmaceut.9b00475","article-title":"P\u2011glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability","volume":"16","author":"Mart\u00ednez-Ch\u00e1vez","year":"2019","journal-title":"Mol. Pharm."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821005387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821005387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:36:39Z","timestamp":1760913399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821005387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":40,"alternative-id":["S1043661821005387"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105954","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105954"}}